Yu-Kyoung Oh, South Korea's minister for food and drug safety, told AIRIS that close cooperation among global regulators is needed to build a new regulatory framework for AI and to apply this flexibly.
US FDA Commissioner Robert Califf said it will be essential for all regulators and international bodies to pursue alignment of expectations and establish harmonized, consensus standards in the rapidly developing area, while continuing to implement these standards at home.
Amgen’s CTO David Reese noted tech and biotech are now unifying and this will qualitatively change how the industry carries out drug discovery and development.
AbbVie’s Ryan Hoshi proposed a "thoughtful human-centric" approach to AI in health and the need for continued stakeholder engagement to ensure greater transparency and dialogue "across the aisle" on risk-based and flexible approaches to regulatory frameworks.

AIRIS 2024: Global Cooperation A Challenge For Regulation Of AI Products

Certainty And Clarity Key Issues For Industry